- Home
- PPBT vs AIOS Comparison
PPBT vs AIOS Comparison
Compare PPBT & AIOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPBT | AIOS |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 4.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PPBT | AIOS |
|---|---|---|
| Price | $0.53 | $0.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.2K | ★ 4.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.43 |
| 52 Week High | $3.00 | $0.71 |
Technical Indicators
Market Signals| Indicator | PPBT | AIOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 62.33 |
| Support Level | N/A | $0.43 |
| Resistance Level | $0.64 | $0.71 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 52.55 | 58.10 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.